Full-Time
Clinical Modality Specialist Structural Heart
Posted on 12/13/2025
Philips
Manufactures sleep therapy and respiratory devices
No salary listed
France
Hybrid
Field-based role with extensive travel across France (up to 80%).
 Medical, Clinical & Veterinary (2) |
|---|
| , |
- You have at least 2–3 years of relevant clinical experience, ideally in structural heart interventions (e.g., Tricuspid, Mitral, LAAO) or invasive ultrasound imaging (transesophageal echocardiography, intracardiac echocardiography).
- You bring hands-on expertise from industry leaders such as Abbott (TriClip, MitraClip, Pascal) or Edwards Lifesciences (Pascal, Evoque), or similar cardiology device experience.
- You hold a Bachelor’s degree or higher in a relevant field (cardiology, ultrasound imaging, biomedical sciences, or related).
- You are fluent in French and English.
- You hold a valid driver’s license.
- You are comfortable traveling extensively (up to 80%) across France.
- Relocation support may be available for the right candidate.
- This is a field-based role with extensive presence in cath labs across France.
- Contribute to one of Philips’ most exciting product launches in Europe, introducing a disruptive innovation that redefines how structural heart interventions are performed.
- Support interventional cardiologists in France during their first 10–15 procedures per site, providing hands-on training and guidance in the cath lab to ensure safe and successful adoption.
- Work within a newly formed European team of clinical specialists, reporting initially to the IGT Devices Leader Europe and later transitioning to the local French IGT Sales Leader.
- Collaborate closely with French sales colleagues, European marketing teams, and experienced global specialists.
- Develop professionally through exposure to top hospitals, key opinion leaders, and cutting-edge interventional cardiology technologies, growing as a subject-matter expert in ultrasound imaging and structural heart procedures.
Philips Respironics designs sleep and respiratory care devices, including CPAP and BiPAP machines, ventilators, and oxygen concentrators, plus related systems. These devices deliver regulated air pressure, support or assist breathing, and provide concentrated oxygen, often paired with software and data tools for monitoring. The division differentiates itself through its long history within Philips and its integrated ecosystem that connects devices with analytics and clinical support across hospital, clinic, and home settings. Its goal is to improve quality of life and clinical outcomes for people with sleep and respiratory conditions by offering reliable devices, patient support, and data-driven care.
Company Size
N/A
Company Stage
Acquired
Total Funding
$5.1B
Headquarters
Murrysville, Pennsylvania
Founded
1891
Simplify's Take
What believers are saying
- BioTelemetry acquisition in 2020 expands remote heart monitoring.
- $479 million settlement in September 2023 closes US litigation.
- New silicone foam validated safe, enabling global device sales.
What critics are saying
- ResMed seizes US sleep market share within 6-12 months.
- FDA consent decree blocks US sales until after 2026.
- January 2024 US ventilation exit halves revenue permanently.
What makes Philips unique
- Pioneered CPAP therapy as standard for sleep apnea since 1976.
- Leads in non-invasive ventilation and home respiratory support.
- Integrates devices with software for data-driven clinical outcomes.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Health Savings Account/Flexible Spending Account
Company News
<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US, subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024. The company’s previously announced 2023-2025 financial outlook remains unchanged, already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more
Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.
In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.
February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.
Register now for your free virtual pass to the Low-Code/No-Code Summit this November 9. Hear from executives from Service Now, Credit Karma, Stitch Fix, Appian, and more. Learn more. Philips Norelco is creating an interactive metaverse experience called Shavetopia in Roblox, based around the Movember trend. For anyone who doesn’t know what that is, Movember is where people grow facial hair for the entire month of November. The portmanteau comes from adding the word mustache to the name of the month